QQQ   281.14 (+0.20%)
AAPL   141.67 (+0.35%)
MSFT   241.01 (+0.28%)
META   109.85 (+0.36%)
GOOGL   95.55 (+0.38%)
AMZN   92.99 (+0.62%)
TSLA   181.79 (+0.53%)
NVDA   155.99 (-0.26%)
NIO   11.15 (+6.19%)
BABA   82.68 (+3.53%)
AMD   73.26 (-0.18%)
T   19.05 (+0.21%)
MU   53.71 (-2.56%)
F   13.77 (+0.15%)
GE   85.70 (+0.05%)
DIS   94.70 (+0.01%)
AMC   7.45 (+0.27%)
PYPL   77.90 (+0.33%)
PFE   49.60 (+0.22%)
NFLX   280.91 (-0.02%)
QQQ   281.14 (+0.20%)
AAPL   141.67 (+0.35%)
MSFT   241.01 (+0.28%)
META   109.85 (+0.36%)
GOOGL   95.55 (+0.38%)
AMZN   92.99 (+0.62%)
TSLA   181.79 (+0.53%)
NVDA   155.99 (-0.26%)
NIO   11.15 (+6.19%)
BABA   82.68 (+3.53%)
AMD   73.26 (-0.18%)
T   19.05 (+0.21%)
MU   53.71 (-2.56%)
F   13.77 (+0.15%)
GE   85.70 (+0.05%)
DIS   94.70 (+0.01%)
AMC   7.45 (+0.27%)
PYPL   77.90 (+0.33%)
PFE   49.60 (+0.22%)
NFLX   280.91 (-0.02%)
QQQ   281.14 (+0.20%)
AAPL   141.67 (+0.35%)
MSFT   241.01 (+0.28%)
META   109.85 (+0.36%)
GOOGL   95.55 (+0.38%)
AMZN   92.99 (+0.62%)
TSLA   181.79 (+0.53%)
NVDA   155.99 (-0.26%)
NIO   11.15 (+6.19%)
BABA   82.68 (+3.53%)
AMD   73.26 (-0.18%)
T   19.05 (+0.21%)
MU   53.71 (-2.56%)
F   13.77 (+0.15%)
GE   85.70 (+0.05%)
DIS   94.70 (+0.01%)
AMC   7.45 (+0.27%)
PYPL   77.90 (+0.33%)
PFE   49.60 (+0.22%)
NFLX   280.91 (-0.02%)
QQQ   281.14 (+0.20%)
AAPL   141.67 (+0.35%)
MSFT   241.01 (+0.28%)
META   109.85 (+0.36%)
GOOGL   95.55 (+0.38%)
AMZN   92.99 (+0.62%)
TSLA   181.79 (+0.53%)
NVDA   155.99 (-0.26%)
NIO   11.15 (+6.19%)
BABA   82.68 (+3.53%)
AMD   73.26 (-0.18%)
T   19.05 (+0.21%)
MU   53.71 (-2.56%)
F   13.77 (+0.15%)
GE   85.70 (+0.05%)
DIS   94.70 (+0.01%)
AMC   7.45 (+0.27%)
PYPL   77.90 (+0.33%)
PFE   49.60 (+0.22%)
NFLX   280.91 (-0.02%)
CVE:NVH

Novoheart - NVH Stock Forecast, Price & News

C$0.53
+0.01 (+1.92%)
(As of 11/20/2020)
Add
Compare
Today's Range
C$0.52
C$0.53
50-Day Range
C$0.53
C$0.53
52-Week Range
C$0.26
C$0.72
Volume
23,066 shs
Average Volume
33,593 shs
Market Capitalization
C$99.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Novoheart

Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada.

Receive NVH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novoheart and its competitors with MarketBeat's FREE daily newsletter.

NVH Stock News Headlines

Novoheart Holdings Inc. (NVH.V)
Novoheart Beats Faster on R&D Pact with Major Partner
Novoheart Quickens Pulses, Wins Another Grant
Cineplex, CP, Novoheart Ride News at 52-Week Highs
IIROC Trading Halt - NVH
Novoheart to Acquire Xellera Therapeutics
See More Headlines
Receive NVH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novoheart and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$423,500.00
Cash Flow
C$0.07 per share
Book Value
C$0.12 per share

Miscellaneous

Free Float
N/A
Market Cap
C$99.98 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Ronald Li B.Sc. (Hons) (Age 49)
    Ph.D., Scientific Co-Founder, CEO & Director
    Comp: $295.17k
  • Dr. Camie Chan B.S. (Age 46)
    B.Sc. (Hons), M.Sc., Ph.D., Interim CFO, COO, Corp. Sec. & Director
    Comp: $312.03k
  • Prof. Kevin Costa B.S. (Age 54)
    Ph.D., Chief Scientific Officer & Scientific Co-Founder
  • Prof. Michelle Khine
    Scientific Co-Founder & Member of Scientific Advisory Board













NVH Stock - Frequently Asked Questions

How have NVH shares performed in 2022?

Novoheart's stock was trading at C$0.53 on January 1st, 2022. Since then, NVH shares have increased by 0.0% and is now trading at C$0.53.
View the best growth stocks for 2022 here
.

What other stocks do shareholders of Novoheart own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novoheart investors own include Invitae (NVTA) and Natera (NTRA).

What is Novoheart's stock symbol?

Novoheart trades on the Canadian Venture Exchange (CVE) under the ticker symbol "NVH."

How do I buy shares of Novoheart?

Shares of NVH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Novoheart's stock price today?

One share of NVH stock can currently be purchased for approximately C$0.53.

How much money does Novoheart make?

Novoheart (CVE:NVH) has a market capitalization of C$99.98 million and generates C$423,500.00 in revenue each year.

How can I contact Novoheart?

The official website for the company is www.novoheart.com. The company can be reached via phone at 604-398 3170.

This page (CVE:NVH) was last updated on 11/30/2022 by MarketBeat.com Staff